Video Insights
Advertisement
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Advertisement
Dr. Nabhan discusses his new book, "Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice."
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
Dr. Sehn also explains why the TRIANGLE study is anticipated to change practices surrounding transplant in MCL.
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
Tycel Phillips, MD, discusses a study evaluating glofitamab in patients with relapsed/refractory mantle cell lymphoma.
Michael Dickinson, MBBS, DMedSc, discusses trials in progress that are evaluating glofitamab with other agents for DLBCL.
Michael Dickinson, MBBS, DMedSc, discusses a phase II trial of glofitamab, a bispecific antibody, in patients with DLBCL.
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Mark Lawler, PhD, discusses insights from European Groundshot Report on survival trends and the future of cancer care.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726